ライフサイエンスコーパス: research and development

1 nMw (the Netherlands Organisation for Health Research and Development).

2 t Change Fund, NHS Greater Glasgow and Clyde Research and Development.

3 us potential biomarkers in varying stages of research and development.

4 Netherlands Organisation for Health Research and Development.

5 nal returns of investments in pharmaceutical research and development.

6 data in real time remains an area for future research and development.

7 ntives that will stimulate new antibacterial research and development.

8 als focusing on change to health systems and research and development.

9 ions, thereby providing a roadmap for future research and development.

10 emanding a strategic rethink of conventional research and development.

11 K, PD, and PK/PD in antibiotic and antiviral research and development.

12 very diverse applications of microbiological research and development.

13 l circuits and discuss directions for future research and development.

14 ed data and bioinformatics tools for vaccine research and development.

15 s limitations, and point to areas for future research and development.

16 this field and offers directions for further research and development.

17 tic to the requirements of biopharmaceutical research and development.

18 s have also occurred recently in stent graft research and development.

19 ng anticancer vaccine that warrants clinical research and development.

20 ansgenic' mouse technology in pharmaceutical research and development.

21 arriers will require considerable additional research and development.

22 -life is a key parameter for optimization in research and development.

23 nding of IP/TP rights is fundamental in both research and development.

24 ubstantial negative effect on pharmaceutical research and development.

25 r should have wide application in biological research and development.

26 US Veterans Health Administration Office of Research and Development.

27 onsensus, and highlight areas needing future research and development.

28 g valuable information for biopharmaceutical research and development.

29 ful knowledge that can reliably guide future research and development.

30 ic materials that are currently under active research and development.

31 ng agenda setting for ecological forecasting research and development.

32 ViiV Healthcare and Janssen Research and Development.

33 gs as well as for applications in antibiotic research and development.

34 ng a critical material challenge for applied research and development.

35 ses clinical trial data for accelerating ALS research and development.

36 nstitutions designed to facilitate nanoscale research and development.

37 ties are reviewed with a focus on the latest research and developments.

38 ome movement on clinical studies and on drug research and development, a precedent has been set that

39 In traditional vaccine research and development, a single high-dose virus chall

40 Research and development activities directed toward comm

41 identified and discussed, as well as current research and development activities of academic, commerc

42 After two decades of research and development activity focussed on orally act

43 The result is a research and development agenda to accelerate malaria el

44 was also supported in part by a Cooperative Research and Development Agreement between NIH and Gilea

45 Program; supported in part by a cooperative research and development agreement between the National

46 to examine ways to incentivise antibacterial research and development and ensure a healthy pipeline o

47 ew, we outline the current state of adjuvant research and development and how formulation parameters

48 e poised to assume the leadership in imaging research and development and in its performance.

49 ded that can both protect the incentives for research and development and reduce the inequities of ac

50 promotion of international public goods (eg, research and development), and surveillance and control

51 are technology and monitoring, pharmacologic research and development, and computing and electronics.

52 Managing this complexity requires ingenuity, research and development, and dedicated resources.

53 review the major relevant trends in genomics research and development, and discuss how these capabili

54 needed to increase funding for tuberculosis research and development, and governments in high-burden

55 The Netherlands Organisation for Health Research and Development, and the NutsOhra Fund.

56 of Research and Development, Health Services Research and Development, and VA Information Resource Ce

57 A RAND-like (Research and Development) appropriateness methodology wa

58 The perspectives for future research and development are also described.

59 limitations of DTI and key areas for future research and development are also discussed.

60 acceptable for RGS, particularly if further research and development are done to improve the perform

61 ion are discussed, and directions for future research and development are identified.

62 These studies imply that further research and development are needed to improve system ut

63 Biomedical Advanced Research and Development Authority (BARDA), PATH, bioCSL

64 Biomedical Advanced Research and Development Authority in the US Department

65 o the cutting edge of thin-film photovoltaic research and development because of their promise for hi

66 listed as priority concerns in a recent WHO research and development blueprint initiative for emergi

67 lsory licensing may undermine incentives for research and development by reducing the value of an inn

68 overnment policies; industry's role in using research and development capabilities to promote healthi

69 l product development and supply, increasing research and development capacity, and addressing gaps i

70 The Ohio State University-Ohio Agricultural Research and Development Center (OSU-OARDC), is a public

71 Houston Veterans Affairs Health Services Research and Development Center of Excellence and the Na

72 nanowires and graphene, and outline the main research and development challenges in the field.

73 1 day (range, 0-74 days), and review by the research and development committee took a median of 15 d

74 he Iowa City Veterans Affairs Medical Center Research and Development Committee.

75 tudy was approved by the Regional Ethics and Research and Development Committees.

76 Research and development connect technology and innovati

77 Using a modified Research AND Development Corporation (RAND)/University o

78 ere is no evidence of an association between research and development costs and prices; rather, presc

79 ) by several orders of magnitudes and reduce research and development costs for government and indust

80 objective insights and analytics to support research and development decision making and planning.

81 the new redox mediators and points to a new research and development direction for DSCs.

82 ction of methanol and DME and outline future research and development directions.

83 c Health England and UK Department of Health Research and Development Directorate.

84 y identifying some key problems that attract research and development efforts as our 21st century beg

85 Research and development efforts for biofuel production

86 International research and development efforts in Africa have brought

87 Recently, research and development efforts on room-temperature sod

88 This manuscript details the process research and development efforts that enabled the synthe

89 f pertinent knowledge expands through future research and development efforts.

90 ersector and interdisciplinary collaborative research and development efforts.

91 n of a sustainable global antibacterial drug research and development enterprise with the power in th

92 law in economics, ranging from large firms, research and development expenditures, gross domestic pr

93 ch laboratories and diagnostic companies for research and development, facilitating collaboration bet

94 Following nearly 40 years of research and development, FDS instruments are now starti

95 spite increased investment in pharmaceutical research and development, fewer and fewer new drugs are

96 capital investments in much more profitable research and development fields.

97 However, small research and development firms spend more per employee t

98 ts included 128 stakeholders engaged in food research and development, food manufacturing and retail,

99 brief account of the status of therapeutics research and development for dengue.

100 global functions, such as support for health research and development for diseases of poverty and str

101 In 2012, US$1.3 billion was spent on research and development for new vaccines for neglected

102 y responsive chemical engineering processing research and development for next-generation technology.

103 hrough pending regulatory reforms, increased research and development for the monitoring, control, an

104 problems encountered in nanocrystal-related research and development, for which the stability of the

105 Region of Scania Research and Development Foundation and Hassleholm Hospi

106 ations could produce a framework to move the research and development from concept to reality.

107 United States-Israel Binational Agricultural Research and Development Fund (BARD) and organized in Ei

108 occur if service firms were to reach median research and development funding.

109 illion, or approximately 11.7 percent of all research-and-development funding received that year.

110 he integration of these two areas as a major research and development goal.

111 However, their research and development has been slowed by several fact

112 arge variability and a lack of resources for research and development have resulted in highly uncerta

113 s, Veterans Health Administration, Office of Research and Development, Health Services Research and D

114 old design are reviewed and areas for future research and development highlighted.

115 The approach to research and development in biomedical science is changi

116 t hold great promises for the advancement of research and development in complex biomedical systems,

117 atively basic in interventional oncology, as research and development in medical imaging focuses on i

118 f graphene materials have stimulated intense research and development in the field of bioelectrochemi

119 This review highlights research and development in the field of emerging viral

120 Finally, an overview of the ongoing research and development in the field of interventional

121 The next decade will witness an explosion of research and development in the neurosciences.

122 on for quantum-scale inputs is key to future research and development in these cognate areas.

123 Research and development in these two important areas ar

124 Reorienting research and development in this way must overcome three

125 It is difficult to determine whether research and development incentives or reducing the cost

126 d genetic surveillance will assist and boost research and development into new antiviral drugs and va

127 lishments, traditional Chinese medicine, and research and development investment in drug discovery.

128 nnovators deciding during trading that their research and development investments should be reduced,

129 alth effects (both intended and unintended), research and development investments, quality and taste

130 ed to consider availability, health effects, research and development investments, reformulated food

131 ic agents have been few, and the funding for research and development is almost non-existent.

132 Considerable research and development is underway to produce fuels fr

133 A significant amount of battery research and development is underway, both in academia a

134 We conclude that a broad range of intensive research and development is urgently needed to produce t

135 ne-vinyl acetate (EVA) copolymers in initial research and development led to commercial drug delivery

136 Beside devices developed at research and development level a brief revision of comme

137 ($3.27 billion) of funding was allocated to research and development (mainly for vaccines and microb

138 ing new vaccines to market, such as funding, research and development, manufacturing, determination o

139 ray Inc, Netherlands Organisation for Health Research and Development, NCI Cancer Center Support, NCI

140 urvivorship care plan and discusses areas of research and development needed to make them part of sta

141 rting a variety of complex queries driven by research and development needs.

142 National Prevention Research Initiative, NHS Research and Development; NHS National Services Scotland

143 This LCA study provides a guide to the research and development objectives that must be achieve

144 mately 20-22% are realized through intensive research and development of 1.5-1.6 eV bandgap perovskit

145 scaffolds represent promising leads for the research and development of a human respiratory syncytia

146 platform for imposing broad restrictions on research and development of all types of transgenic tree

147 ppear that from an industry perspective, the research and development of antibiotics should be an att

148 Advances in research and development of antiviral inhibitors targeti

149 l investment from government and industry in research and development of cancer preventive agents; a

150 re taking an increasingly active role in the research and development of catheters and catheter inser

151 This article reviews the progress in the research and development of CQDs with an emphasis on the

152 Future research and development of D3R-selective antagonists an

153 Relevant animal models are important for HCV research and development of drugs and vaccines.

154 ble progress is constantly being made in the research and development of drugs for rare disorders.

155 her antibiotic-resistant bacteria to support research and development of effective drugs.

156 The major barrier to research and development of effective interventions for

157 e and our patients will benefit from further research and development of evidence-based treatments.

158 tical studies bring the new insights for the research and development of intercalation compounds as e

159 undoubtedly become a new paradigm for future research and development of metal additive manufacturing

160 This achievement is a turning point in the research and development of Mg electrolytes that has dee

161 idelines are presented to facilitate further research and development of more optimized CEP systems.

162 s review collocates current knowledge in the research and development of nanocelluloses and emphasize

163 This work can significantly benefit the research and development of nanoscale STT-MRAM.

164 ds have been increasingly used to accelerate research and development of new biomaterials.

165 Beyond continued research and development of new drugs, a focus on drug r

166 The most recent progress in the research and development of new materials as well as the

167 0 years, the recent enhanced activity in the research and development of new TB drugs is extremely en

168 s to improving this situation is driving the research and development of new technologies for toilets

169 sive summary of the preclinical and clinical research and development of nintedanib from the initial

170 nt VVC and highlight the need for additional research and development of novel therapeutics targeting

171 ew article takes a retrospective look at the research and development of OPV, and focuses on recent a

172 The interpretation of existing research and development of recommendations should be do

173 regulatory issues that deter progress of AR research and development of therapeutics targeting AR an

174 ion and suggest promising avenues for future research and development of therapies.

175 Over the past 15 years, research and development of these materials have become

176 So far, research and development of tuberculosis vaccines has re

177 IRD facilitates the research and development of vaccines, diagnostics and th

178 An important aspect in the research and development of white light-emitting diodes

179 Finally, some perspectives on the future research and development of YSNs are provided.

180 surveillance, community-based participatory research, and development of a diverse clinical and publ

181 stimulating further investment in education, research, and development of these dedicated small-anima

182 on for non-polluting vehicles, and extensive research and development on all aspects of this technolo

183 Despite more than two decades of research and development on nucleic acid vaccines, there

184 To date, research and development on such a framework have proven

185 ll succeed in revolutionising pharmaceutical research and development only if these interactions are

186 ing a route towards streamlined micro-device research and development onto clinical use.

187 rrent energy landscape and discusses several research and development opportunities and pathways that

188 oscopy may find applications in agrochemical research and development or in studies of wax deposition

189 s of medical instruments, many remain in the research and development phase despite persistent effort

190 We analysed the research and development pipeline of drugs and vaccines

191 st-effectiveness analysis can help to inform research and development portfolio prioritization decisi

192 nd incorporate sustainability goals into the research and development process will benefit green chem

193 Korean Seoul City Research and the National Research and Development Program for Cancer Control, Min

194 National Forensic Mental Health Research and Development Programme, UK Ministry of Justi

195 Research and development programs are underway for a new

196 elevant genes as candidates for therapeutics research and development programs to be identified.

197 uel Standard and U.S. Department of Energy's research and development programs, often lack historical

198 ks of AD-continues to drive significant drug research and development programs.

199 Research and development proposals focus on sustainable

200 Health and Social Care Research and Development, Public Health Agency, Northern

201 s, Veterans Health Administration, Office of Research and Development, Quality Enhancement Research I

202 s, Veterans Health Administration, Office of Research and Development, Quality Enhancement Research I

203 There are also several key research and development questions that must be addresse

204 f $100 million in annual subsidies, formed a research and development (R&D) consortium called Sematec

205 latform MSI analysis within a pharmaceutical research and development (R&D) environment.

206 the available United States data on academic research and development (R&D) expenditures and the numb

207 for health with additional donor spending on research and development (R&D) for diseases of poverty.

208 Research and development (R&D) for pediatric antiretrovi

209 mines data on international trends in energy research and development (R&D) funding, patterns of U.S.

210 t-based model of strategic link formation in Research and Development (R&D) networks.

211 pplying life cycle assessment (LCA) early in research and development (R&D) to guide emerging technol

212 cent trends in United States expenditures on research and development (R&D).

213 esearch; Netherlands Organisation for Health Research and Development; Research Institute for Disease

214 Funders need to prioritize their scarce research and development resources.

215 The Netherlands Organisation for Health Research and Development, Sanquin Blood Supply, Chest He

216 partment of Veterans Affairs Health Services Research and Development Service

217 partment of Veterans Affairs Health Services Research and Development Service.

218 partment of Veterans Affairs Health Services Research and Development Service.

219 artment of Veterans Affairs, Health Services Research and Development Service.

220 ole; and the ways that federal policy toward research and development should respond to scientific ad

221 re discussions among scientists, physicians, research and development specialists, and public health

222 puts have failed to keep pace with increased research and development spending.

223 ry efficiencies approaching 20 per cent, the research and development targets for CdTe are to reduce

224 Overall, we identify four avenues of research and development that can serve the dual purpose

225 This essay describes the research and development that led to the VLP vaccines; d

226 Research and development that supports new technological

227 ARC, The Netherlands Organisation for Health Research and Development, the Italian Ministry of Health

228 ain mechanisms and significant investment in research and development, the majority of analgesics ava

229 Regrouping patient care, diagnostics, research, and development, the University Hospital Insti

230 use of reduced funding for antimalarial drug research and development; therefore, the usefulness of c

231 strate the potential to substantially reduce research and development time and to increase speed to m

232 significant differences in credentialing or research and development times across review types (exem

233 eements on access to essential medicines and research and development to ensure availability of new e

234 Further research and development to overcome current challenges

235 cine, systems-based practice, and continuing research and development toward improving acute and chro

236 perform an analysis of global cancer surgery research and development trends over the last 10 years a

237 ng by disease, cross-cutting theme, and by a research and development value chain describing the type

238 Questionnaire -2.64 [95% CI -6.43 to 1.15]; Research and Development version 1 short-form-36 4.08 [-

239 Office of Research and Development, Veterans Health Administration

240 Substantial research and development will be required for E-BC comme

241 Also discussed is the status of research and development with regard to biosynthetically

242 Significant research and development would be required and a wide ra

243 Netherlands Organization for the Health Research and Development (ZonMw 92003545).

244 Netherlands Organisation for Health Research and Development (ZonMW), Region Vastra Gotaland

245 Netherlands Organization for Health Research and Development (ZonMw).

246 ard; The Netherlands Organisation for Health Research and Development (ZonMw); the Ministry of Health